Compare DIN & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DIN | CYPH |
|---|---|---|
| Founded | 1958 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 378.8M | 321.1M |
| IPO Year | 1994 | 2019 |
| Metric | DIN | CYPH |
|---|---|---|
| Price | $36.02 | $2.96 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $35.33 | N/A |
| AVG Volume (30 Days) | 599.9K | ★ 11.2M |
| Earning Date | 11-04-2026 | 11-16-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | N/A | ★ 103.87 |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $879,300,000.00 | $1,500,000.00 |
| Revenue This Year | $8.75 | N/A |
| Revenue Next Year | $4.72 | $408.92 |
| P/E Ratio | $38.12 | ★ N/A |
| Revenue Growth | ★ 8.25 | N/A |
| 52 Week Low | $23.97 | $0.49 |
| 52 Week High | $39.68 | $4.19 |
| Indicator | DIN | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 64.95 | 45.78 |
| Support Level | $33.17 | $2.22 |
| Resistance Level | $36.86 | $3.35 |
| Average True Range (ATR) | 1.85 | 0.42 |
| MACD | 0.49 | -0.07 |
| Stochastic Oscillator | 65.59 | 20.56 |
Dine Brands Global Inc owns and franchises thousands of restaurants under the International House of Pancakes (IHOP), Applebee's Neighborhood Grill + Bar (Applebee's), and the Fuzzy's Taco Shop (Fuzzy's) names. The company conducts its business through three reportable segments: Franchise, Company-owned restaurants, and Rental. The majority of its revenue is generated from the Franchise segment, which consists of IHOP, Applebee's, and Fuzzy's franchise operations and generates revenue mainly from royalties and advertising fees from several IHOP, Applebee's, and Fuzzy's franchised restaurants, in addition to revenues from the sale of proprietary IHOP and Fuzzy's products to its franchisees. Geographically, the majority of the company's revenues is generated from its domestic market.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.